New Investor Member: The Riverside Company is a global private investment firm focused on driving growth for companies at the smaller end of the middle market in Europe, North America and Australia. With approximately $13 billion in assets under management, Riverside has completed more than 1,000 investments since its founding in 1988. Healthcare investing is one of Riverside’s most active specializations, with more than 200 deals completed in the space. The firm’s current portfolio, inclusive of add-ons, features more than 65 healthcare company investments.
In Europe, the latest Riverside Europe Fund targets control buyouts of companies with up to €30 million EBITDA. Current European healthcare investments include:
+ A.forall (Global specialty pharma group which develops value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment)
+ BioDue spa (Italian CDMO focused on the research, development, production and commercialization of cosmetic products, medical devices and food supplements, both liquid and solid)
+ Dastex Reinraumzubehör GmbH & Co. KG (European leader in contamination control for cleanrooms)
+ HTBA (HealthTech BioActives) (Global leader in natural flavonoids and B12 derivatives, producing solutions for Pharmaceutical APIs, Taste Modulation, Health Functional, and Animal Nutrition, from naturally sourced materials)
Visit https://lnkd.in/d_f39Z_N to learn more about Riverside's Healthcare specialization.
Damien Gaudin, Jeroen Lenssen, Tommy Seddon, Dan Parksjö, Maxime Meulemeester, Laura de Palacio Aragón, Nicola Philipp Tomaschko, Bence Putnoky,Jaime García-Oliveros Serrano, Filip Van de Vliet
#privateequity #investing #healthcare #lifesciences #medtech #pharma #naturalingredients #healthcaretechnology #foodsupplements #CDMO #CRO #GMP #API
Sr. Business Development Executive, Strategic Accounts for Echo Global Logistics
4moOne of the best teams I’ve had the pleasure of working with! And the office is gorgeous as well!